Edwards Lifesciences (EW) CVP sells 11,340 shares after option exercise

Rhea-AI Filing Summary

Edwards Lifesciences executive Donald E. Bobo Jr., CVP, Strategy/Corporate Development, exercised employee stock options for 11,340 shares and on the same day sold 11,340 shares of common stock at a weighted average price of $85.9286, under a pre-established Rule 10b5-1 trading plan. After these transactions, he directly owned 21,266.2532 shares, with additional indirect holdings of 38,900.5862 shares through a 401(k) and 121,756 shares held by a trust.

Insider Trade Summary

Net Seller: 11,340 shares ($974,430)

Net Sell 5 txns

Insider BOBO DONALD E JR

Role CVP,Strategy/Corp Development

Sold 11,340 shs ($974K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Acquire)	11,340	$0.00	--
Exercise	Common Stock	11,340	$59.2567	$672K
Sale	Common Stock	11,340	$85.9286	$974K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Acquire) — 22,680 shares (Direct); Common Stock — 32,606.253 shares (Direct); Common Stock — 38,900.586 shares (Indirect, 401(k))

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. This transaction was executed in multiple trades at prices ranging from $85.665 to $86.380. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/02/2026 - 05:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOBO DONALD E JR

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP,Strategy/Corp Development

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		M(1)		11,340	A	$59.2567	32,606.2532	D
Common Stock	03/02/2026		S(1)		11,340	D	$85.9286(2)	21,266.2532	D
Common Stock								38,900.5862	I	401(k)
Common Stock								121,756	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$59.2567	03/02/2026		M			11,340	06/08/2019	05/07/2026	Common Stock	11,340	$0.0000	22,680	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.

2. This transaction was executed in multiple trades at prices ranging from $85.665 to $86.380. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did EW executive Donald E. Bobo Jr. report on this Form 4?

Donald E. Bobo Jr. reported exercising employee stock options for 11,340 shares and selling 11,340 shares of Edwards Lifesciences common stock. Both transactions occurred on March 2, 2026, reflecting an option exercise followed by an open-market or private sale on the same day.

At what prices did Donald E. Bobo Jr. sell Edwards Lifesciences (EW) shares?

He sold 11,340 shares at a weighted average price of $85.9286 per share. A footnote explains the sale was executed in multiple trades with prices ranging from $85.665 to $86.380, with the reported figure representing the weighted average sale price.

How many Edwards Lifesciences (EW) shares does Donald E. Bobo Jr. own after these transactions?

Following the reported transactions, he directly owned 21,266.2532 shares of Edwards Lifesciences common stock. He also had indirect ownership of 38,900.5862 shares through a 401(k) plan and 121,756 shares held by a trust, as reflected in the filing data.

Was the Edwards Lifesciences (EW) insider sale by Donald E. Bobo Jr. under a 10b5-1 plan?

Yes. A footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted by Donald E. Bobo Jr. on February 27, 2025. Such plans pre-schedule trades to help insiders systematically sell or acquire shares over time.

What type of derivative security did Donald E. Bobo Jr. exercise in the Edwards Lifesciences Form 4?

He exercised an employee stock option, labeled as an "Employee Stock Option (Right to Acquire)". This derivative exercise converted 11,340 option rights into an equal number of Edwards Lifesciences common shares before the same number of shares was sold.

What is Donald E. Bobo Jr.’s role at Edwards Lifesciences (EW) mentioned in the Form 4?

The filing identifies Donald E. Bobo Jr. as an officer of Edwards Lifesciences, holding the title "CVP, Strategy/Corp Development." This indicates a senior leadership position overseeing corporate strategy and corporate development activities at the company.